News | Cardiac Imaging | May 10, 2016

Study of 752 patients finds cardiac magnetic resonance better predicts risk at five year follow-up

cardiac magnetic resonance, CMR, SPECT, major adverse cardiovascular events, MACE predictor, Annals of Internal Medicine study

May 10, 2016 — Cardiovascular magnetic resonance (CMR) is a stronger predictor of risk for major adverse cardiovascular events (MACE) than single-photon emission computed tomography (SPECT) at five years follow-up. The findings are published in Annals of Internal Medicine.

CMR is an MRI scan that focuses on the area around the heart. Unlike SPECT, CMR does not involve ionizing radiation and the large CE-MARC (Clinical Evaluation of Magnetic Resonance imaging in Coronary heart disease) study demonstrated that CMR had high diagnostic accuracy, with higher sensitivity and negative predictive value compared with SPECT.

However, data on the prognostic value of CMR remain limited. A predefined objective of CE-MARC was to assess the ability of CMR and SPECT to predict MACE at five-year follow-up. To do so, researchers studied 752 patients from the CE-MARC study who were being investigated for suspected coronary heart disease. The patients were scheduled to undergo CMR and SPECT in random order, followed by X-ray coronary angiography (the reference standard) within four weeks. The investigators followed up with patients every year for five years to assess for MACE.

The researchers found that at five-year follow-up, CMR was a stronger predictor of risk for MACE than SPECT, independent of clinical cardiovascular risk factors, angiography result or initial patient treatment. The researchers conclude that CMR should be considered a robust alternative to SPECT for the diagnosis and management of patients with suspected coronary heart disease.

For more information: www.annals.org


Related Content

News | FDA

Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ...

Time February 03, 2026
arrow
News | Interventional Radiology

Feb. 2, 2026 — GE HealthCare has announced that Allia Moveo has received U.S. Food and Drug Administration (FDA) 510(k) ...

Time February 02, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 27, 2026 — Hyperfine has announced results from the largest data set to date evaluating stroke detection with its ...

Time January 28, 2026
arrow
News | Radiology Education

Jan. 22, 2026—The American Roentgen Ray Society (ARRS) will host a live virtual symposium, "Medical Imaging for ...

Time January 28, 2026
arrow
News | Radiology Imaging

Jan.26, 2026 — SimonMed Imaging has unveiled an updated brand and the launch of SimonMed Longevity, a new division ...

Time January 27, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 20, 2026 — Hyperfine, the developer of the first FDA-cleared AI-powered portable MRI system for the brain — the ...

Time January 20, 2026
arrow
News | Stroke

Dec. 12, 2025 — Hyperfine, Inc. has announced that it has received FDA clearance for a new multi-direction diffusion ...

Time December 15, 2025
arrow
News | Artificial Intelligence

Dec. 1, 2025 — Researchers at the University of California, Berkeley and University of California, San Francisco have ...

Time December 10, 2025
arrow
Feature | Uzay Emir and Stephen Sawiak

Healthcare has reached a critical juncture. The World Economic Forum estimates that global medical costs will see double ...

Time December 04, 2025
arrow
Subscribe Now